Lv3
251 积分 2021-08-23 加入
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection
1个月前
已完结
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
1个月前
已完结
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
1个月前
已完结
Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study
2个月前
已完结
Breathomics Analysis for Early Diagnosis of Lung Cancer Based on PTR‐TOF MS: A Large Sample Size Cross‐Sectional Study
2个月前
已完结
Novel bioengineered drugs with immunotherapies for malignant pleural effusion: Remodulate tumor immune microenvironment and activate immune system
2个月前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
3个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
4个月前
已完结
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
4个月前
已完结
A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040)
4个月前
已完结
皖公网安备34019202002308
